• Gossamer Bio set a structured private placement with gross proceeds up to USD 250 million to fund seralutinib through potential FDA approval.
• USD 150 million is committed, split between USD 25 million at an initial closing expected around Aug. 24, 2026.
• Another USD 125 million would fund at a second closing upon FDA acceptance of a PAH NDA in 2026.
• Initial closing issues pre-funded warrants priced at USD 0.1399, equivalent to USD 0.14 per share less a USD 0.0001 exercise price.
• Second closing includes FDA Approval Warrants; full cash exercise at USD 0.19 per share could add up to USD 100 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gossamer Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260821107693) on August 21, 2026, and is solely responsible for the information contained therein.